Stockscreener 앱 받기
421.67
1.02%
-4.33
시간 외 거래:
422.00
0.33
+0.08%
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Committee stocks on the move: Uber and Vertex Pharma - MSN
RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Rating, Lowe - GuruFocus
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint - sharewise.com
Vertex’s new pain, blood disorder drugs miss Wall Street expectations - BioPharma Dive
Vertex shares slide on reliance on old product - The Pharma Letter
Why Vertex Skidded Despite Its Beat-And-Raise Quarter - Investor's Business Daily
Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration - TipRanks
Analyst Barclays Maintains 'Equal-Weight' for VRTX, Raises PT to $414 | VRTX Stock News - GuruFocus
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio - BioSpace
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $466 From $471, Maintains Market Perform Rating - MarketScreener
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $414 From $408, Maintains Equalweight Rating - MarketScreener
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $445 From $455, Maintains Hold Rating - MarketScreener
VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | - GuruFocus
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook - TradingView
RBC Lowers Price Target on Vertex Pharmaceuticals to $415 From $423, Keeps Sector Perform Rating - MarketScreener
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays - TipRanks
Bank of New York Mellon Corp Lowers Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of Montreal Can Sells 50,652 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Outpaces Expectations With Fresh Growth - Finimize
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedJobs Report & Free AI Powered Buy and Sell Recommendations - newser.com
Vertex Pharmaceuticals (VRTX) Reports Strong Q3 2025 Earnings with 11% Revenue Growth - GuruFocus
Vertex Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential - newser.com
Vertex Reports Third Quarter 2025 Financial Results - BioSpace
Vertex’s cystic fibrosis sales beat expectations, as newer drugs miss - The Boston Globe
Vertex Pharmaceuticals (VRTX) Beats Q3 Expectations, Shares Fall - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock: Strong Q3 Results Drive 11% Revenue Growth - parameter.io
Earnings call transcript: Vertex Q3 2025 beats forecasts, stock gains - Investing.com
Vertex falls despite Q3 double beats as 2025 revenue guidance narrowed - Seeking Alpha
Vertex’s Cystic Fibrosis Sales Beat, as Newer Drugs Miss - Bloomberg.com
Vertex Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vertex Pharmaceuticals (VRTX) Q3 Earnings Surpass Expectations - GuruFocus
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Vertex Pharmaceuticals Grows Past Cystic Fibrosis With New Hits - Finimize
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs - MSN
Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs - MarketScreener
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations - Yahoo Finance
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book - MSN
After pain setback, Vertex spotlights renal portfolio in expectation-beating Q3 - FirstWord Pharma
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $4.80 per Share, vs. FactSet Est of $4.58 - MarketScreener
Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q3 Adjusted EPS $4.80, vs. FactSet Est of $4.58 - MarketScreener
Vertex Beats Estimates on Strong Sales of Cystic Fibrosis Drugs - Bloomberg.com
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain. - MSN
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceWeekly Trade Report & Smart Investment Allocation Tips - newser.com
Published on: 2025-11-03 07:39:53 - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Analyst Calls & Growth Focused Entry Reports - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Tredje AP fonden - MarketBeat
Telos Capital Management Inc. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Torray Investment Partners LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Welch & Forbes LLC - MarketBeat
South Dakota Investment Council Sells 10,780 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-03 04:36:10 - newser.com
Mission Wealth Management LP Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Arkadios Wealth Advisors - MarketBeat
2.22%
0.63%
자본화:
|
볼륨(24시간):